Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Current Diabetes Reports
Volume 20, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-05
DOI
10.1007/s11892-020-01349-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
- (2020) Jeffrey Budd et al. AMERICAN JOURNAL OF MEDICINE
- Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
- (2020) Kenneth Cusi DIABETES CARE
- NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
- (2020) Naim Alkhouri EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
- (2020) Kenneth Cusi LIVER INTERNATIONAL
- NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
- (2020) Giovanni Targher et al. GUT
- 1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
- (2020) ROMINA LOMONACO et al. DIABETES
- NASH in Lean Individuals
- (2019) Ramy Younes et al. SEMINARS IN LIVER DISEASE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents
- (2019) Antonino Di Pino et al. ENDOCRINE REVIEWS
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications
- (2019) Saumya Jayakumar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
- (2019) Hannes Hagström et al. GASTROENTEROLOGY
- Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
- (2019) Fernando Bril et al. DIABETES CARE
- Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
- (2019) Zobair M. Younossi et al. DIABETES CARE
- Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality
- (2019) Martijn C. G. J. Brouwers et al. DIABETOLOGIA
- A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis
- (2019) Adel Hammoutene et al. JOURNAL OF HEPATOLOGY
- Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
- (2019) Mohammed Eslam et al. Nature Reviews Gastroenterology & Hepatology
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016
- (2019) Yiling J. Cheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
- (2018) Varman T. Samuel et al. Cell Metabolism
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial
- (2018) Atsushi Tanaka et al. HEART AND VESSELS
- Should we undertake surveillance for HCC in patients with NAFLD?
- (2018) Ramy Younes et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Incretin drugs as modulators of atherosclerosis
- (2018) Enrique Gallego-Colon et al. ATHEROSCLEROSIS
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
- (2018) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies
- (2018) Ken Lee Chin et al. CARDIOVASCULAR RESEARCH
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
- (2017) Fernando Bril et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
- (2016) Romina Lomonaco et al. DIABETES CARE
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Nonalcoholic steatohepatitis in nonobese patients: Not so different after all
- (2016) Kenneth Cusi HEPATOLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- The Natural Course of Non-Alcoholic Fatty Liver Disease
- (2016) Luis Calzadilla Bertot et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
- (2016) Anna Vanderheiden et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
- (2015) Hiroyuki Kato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
- (2015) Pierre Blais et al. DIGESTIVE DISEASES AND SCIENCES
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
- (2013) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
- (2011) Tomoyuki Iwasaki et al. HEPATO-GASTROENTEROLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now